Latest Articlesddd
A False Reason for Unwarranted Selling of CRISPR/Cas9 Gene Editing Shares CRISPRs are bacterial immune systems …
The Week in Review #20 THE MARKET - My friend asked: “Are you scared?” “Of what?” …
Exelixis: Delightful Overseas Cabozantinib News Ipsen (EPA:IPN) announced that the Committee for Medicinal Products for Human Use …
Regeneron (REGN) and Alnylam (ALNY) announced a collaborative agreement aimed at identifying RNAi therapeutics for the chronic liver disease …
In spite of their successes, Immuno-oncology products, which we still like to call immunotherapy for several …
Arena Pharmaceuticals (ARNA) announced positive Phase 2 results from the OASIS trial for etrasimod in ulcerative colitis (UC). The Drug: Etrasimod is a …
What Do We Make of the Following Good News? HERON THERAPEUTICS Will HTX-011 Help in the …
Exelixis (EXEL) completed the submission of a supplemental New Drug Application (sNDA) to the FDA for Cabometyx® …
Prohost Letter #419 RE-EVALUATION ONLY - The Prohost Portfolio comprises biotechnology and biopharmaceutical companies, that we …
Alnylam (ALNY) announced that Sanofi Genzyme declined its opt-in for the development and commercialization of the RNAi …
The Week in Review #19 Targeting the Root-Cause of Diseases - Investing in the Future is …
Extremely important news has come from Montreal, Canada carrying the announcement by Theratechnologies (TSX:TH) and its partner TaiMed …
Regeneron’s (REGN) pipeline products have still a lot of good news to announce. The latest is about …
On March 4, 2018, Aimmune Therapeutics (AIMT) – a biopharmaceutical company developing treatments for potentially life-threatening food allergies …
Prohost Letter #418 Observing Queer Stories PORTOLA - Portola (PTLA) has been granted approval of an …
FERTILITY Fertility is what guarantees the presence of humans on the planet Earth. The reproductive system …
The Food and Drug Administration (FDA) approved AstraZeneca (AZN) Checkpoint inhibitor drug Imfinzi® (durvalumab) for patients with unresectable Stage III non-small …
Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for …
Portola Pharmaceuticals and the CHMP’s Oral Explanations for Andexanet Alfa and Betrixaban Portola (PTLA) announced that the Committee for …
The Week in Review #18 The Market - The stock market recuperated most of its losses …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
